Search results
Results from the WOW.Com Content Network
Atomoxetine, formerly sold under the brand name Strattera [12], is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) [13] and, to a lesser extent, cognitive disengagement syndrome (CDS). [14] [15] [16] It may be used alone or along with stimulant medication.
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved.
Atomoxetine is sold under the brand name Strattera and was first approved for medical use in the United States in 2002. [1] Its indication is for the treatment of attention deficit hyperactivity disorder (ADHD) in children over 6 years of age, adolescents and adults. [2]
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD Suboxone ( buprenorphine/naloxone ) - a partial opioid agonist used in the treatment of opioid use disorder T
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).
The medication was discontinued in 2002 for commercial reasons. [ 6 ] [ 13 ] [ 14 ] However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021. [ 6 ] [ 15 ] [ 16 ] Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance .
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: